Karyopharm Therapeutics Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
Karyopharm entered a forbearance agreement dated September 10, 2026 with all lenders under three debt facilities: Term Loans (Highbridge, Braidwell, Context, others), 9% Convertible Notes due 2028 and 2029, and a Revenue Interest Financing Agreement (Healthcare Royalty Partners). The forbearance suspends enforcement of payment defaults through October 15, 2026, in exchange for $20M in Series A convertible preferred stock (20,000 shares at $1,000 liquidation preference, convertible at $1.62/share). Additional forbearance consideration includes 2% per annum additional interest on deferred note payments. All debt counterparties are consenting lenders.
Why this rating
Company faces imminent covenant breaches and payment defaults on >$50M+ debt (relative to $37M market cap), forcing dilutive restructuring. Forbearance buys ~5 weeks; heavy compliance burden and asset controls suggest financial distress. Material near-term.
Price action (we called it negative)
before filing · preread $1.64 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.